“Four doses of an experimental vaccine to protect against Lyme disease reduced the number of tick-borne infections by more than 70 percent, according to Pfizer and Valneva, the pharmaceutical companies developing the shot.

Pfizer said in a statement the companies are ‘confident in the vaccine’s potential’ and plan to submit the data to regulatory authorities, even though it missed a statistical cutoff for success. If approved, it could become the only Lyme disease vaccine available for people — although it would not be the first.”

From Washington Post.